Across the country, oncology practices are recognizing the importance of developing and continually improving quality care.1,2 Patients with MPNs are a population that may benefit from specialized, disease-specific programs. The elements of the quality initiatives described in these materials have not been validated and approved for securing accreditation or reimbursement.

Elements of an ongoing MPN quality program may include:

Use the resources and videos found on this site if you are ready to take a proactive approach to developing quality programs for your patients living with MPNs.

Perspectives on Quality Initiatives in MPNs

Physician Perspectives on MPNs

Robyn Scherber, MD, MPH, is Sr. Director, Medical Affairs at Incyte. Additionally, she is an Assistant Professor of Medicine at the University of Texas Health Science Center at San Antonio. She provides a physician perspective on the importance of quality initiatives for patients with MPNs and discusses assessing symptom burden, conducting spleen assessments, and addressing patient needs concretely and realistically.

Physician Perspectives on MPNs

John Winters, MD, Staff Physician at New England Cancer Specialists, offers a physician's perspective on the practical application of quality initiatives and the importance of regular symptom tracking and assessment for patients with MPNs.

Practice Manager Perspective on MPNs

Kellie Mozingo, RN, Practice Manager at Hunterdon Hematology Oncology, provides her perspective on the importance of quality initiatives for patients with MPNs, along with tips for implementing an MPN quality initiative in an oncology practice.

The Need for Quality Initiatives in Oncology

Michael Reff, RPh, MBA, Founder and Executive Director of the National Community Oncology Dispensing Association (NCODA), explains the need for practices and pharmacists to learn about rare cancers so they are better prepared to provide quality patient care. Watch as he discusses the importance of quality initiatives for patients with myeloproliferative neoplasms (MPNs).

Risk Assessment and Quality Initiatives in Myelofibrosis (MF)

Julianne Orr Darling, PharmD, BCOP, an Oncology and Clinical Pharmacist at Indiana University Health, talks about how risk stratification is an important part of managing patients with MF. Review risk stratification criteria and how pharmacists can create a list of patients for a potential quality initiative. Learn more by watching this video (a downloadable brochure about MF risk is available below as a PDF).

Quality Intervention in Advanced Polycythemia Vera (PV)

Neal Dave, PharmD, Pharmacy Area Manager, Texas Oncology, talks about PV as a hematologic malignancy that may become advanced in a subset of patients despite treatment with hydroxyurea and phlebotomy, resulting in ineffective disease control.3-6 For more information about PV and quality interventions, watch this PV walkthrough (available for download below as a PDF).

Implementing a Quality Initiative for Patients With Polycythemia Vera (PV)

Neal Dave, PharmD at Texas Oncology, describes the steps his team uses to work with patients and medical personnel with the goal of improving patient outcomes. Explore a multidisciplinary approach that pharmacists can take to implement a quality initiative for patients with PV. View the video.

PDF Icon

A Practice Manager’s Perspective on Quality Initiatives for Patients With MPNs

Kelly Mozingo, RN, Practice Manager at Hunterdon Hematology Oncology teaches you concrete quality initiative goals and implementation strategies.

Download PDF
PDF Icon

A Physician’s Perspective on Quality Initiatives for Patients With MPNs

Dr John Winters gives his opinion about the importance of regular symptom assessment and tracking when developing quality initiatives for patients with MPNs.

Download PDF
Additional Resources for Implementing Quality Initiatives in MPNs
PDF Icon

Implementing a Quality Intervention for Advanced PV

Use this downloadable brochure as a resource when implementing a quality intervention for PV.

Download PDF
PDF Icon

Identifying Risk and Setting Up Quality Treatment Programs for Patients With MF

This brochure provides information that may help you identify and evaluate risk profiles among your patients with MF. This downloadable resource offers insight into strategies for assessing and monitoring risk.

Download PDF
PDF Icon

Symptom Burden Quality Initiative Brochure

View a guide for pharmacy directors and clinical pharmacists that can help clinicians identify patients with burdensome symptoms of MPNs.

Download PDF
Power Point (PPT) Icon

Developing Quality Initiatives

You play an important role in helping to build quality programs for patients living with MPNs. This presentation is intended for US healthcare professionals responsible for population-based decision making at hospitals and US oncology practices.

View Slide Deck
References

1. Hewitt M, Simone JV. Ensuring Quality Cancer Care. Washington, DC: National Academy Press, 1999. 2. Neuss MN, Desch CE, McNiff KK, et al. A process for measuring the quality of cancer care: the Quality Oncology Practice Initiative. J Clin Oncol. 2005;23(25):6233-6239. 3. Parasuraman S, DiBonaventura M, Reith K, Naim A, Concialdi K, Sarlis NJ. Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review. Exp Hematol Oncol. 2016;5:3. 4. Mascarenhas J. A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2016;16 suppl:S124-S129. 5. Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017;129(6):680-692. 6. Spivak JL, Considine M, Williams DM, et al. Two clinical phenotypes in polycythemia vera. N Engl J Med. 2014;371(9):808-817.